COVID-19 rapid test ImmunoPass™

proteinSARS-COV-2serum

ImmunoPass™ SARS-Cov-2 Neutralizing Antibody (NAb) Rapid Test is a rapid lateral flow chromatographic immunoassay intended for the semi-quantitative measurement of neutralizing antibody in human serum or plasma (sodium heparin, potassium and acid dextrose citrate). The ImmunoPass™ SARS-Cov-2 Neutralizing Antibody (NAb) Rapid Test measures functional neutralizing antibodies (NAbs) within 10 minutes, unlike traditional test which require days. The ImmunoPass™ test kit does not utilize live biological materials and does not require the strict biosafety protocol associated with live virus samples. The ImmunoPass™ Neutralizing Antibody (NAb) test demonstrates the ability of antibodies to BLOCK the binding of the RBD on spike protein to ACE2, the cellular receptor. RBD is the principle neutralizing determinant for SARS-CoV-2. BLOCK the COVID virus, providing immunity protection against infection and re-infection NEUTRALIZING ANTIBODIES inactivate the COVID-19 virus and are ASSOCIATED WITH IMMUNITY NON-NEUTRALIZING ANTIBODIES do not block or neutralize COVID, thus provide no protection against re-infection. The ImmunoPass™ Neutralizing Antibody tests measures titer levels, which indicate the amount of neutralizing antibodies in a blood sample. Titers are measured by ratios, where a higher ratio (1:320 compared to 1:8) indicates higher titer levels. A higher titer level means that the blood can be diluted many times and still produce a virus-neutralizing response.